- Dr Carsten Linnemann
- Dr Ton Schumacher
Dr Carsten Linnemann
- % Shareholding
- Number of employees
- Raised from a Series A financing in 2020
Unless stated all financials at 30 September 2022
Neogene is developing a process to manufacture a wholly personalised autologous product employing engineered neoantigen-specific T cells.
Neogene, a Netherlands based company, was founded in 2018, based on the work of Dr Ton Schumacher, a leading cancer immunologist, and Dr Carsten Linnemann who was previously associate director of next generation T cell therapy at Kite Pharma. In 2020 Syncona co-led the $110m Series A financing round, committing $19m.
The company’s engineered T cells target mutated proteins, or neo-antigens, found in cancer cells as a consequence of cancer-associated DNA mutations. Neo-antigens render tumor cells vulnerable to detection by T cells. Neogene’s proprietary technology platform aims to identify TCR genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel approach intends to deliver a tailored set of TCR genes for each individual patient, which will be engineered into patient-derived T cells directing them toward neo-antigens in tumor cells, with the goal of providing a fully personalized engineered T cell therapy for cancer.
In November 2022 agreement was reached with AstraZeneca for the sale of Neogene in an acquisition worth up to $320 million. The transaction is expected to close in the first quarter of CY2023.
- The company is developing an engineered T Cell Receptor (TCR) therapeutic approach for solid tumours based on a patient’s own neoantigens (personalised autologous cell therapy)
Unmet medical need
Limited treatment options for relapsed/refractory patients with advanced solid tumours that have progressed through front line therapies.
Cell therapies offer the potential for deep and durable responses in the populations as evidenced by Iovance’s tumor inflitrating lymphocyte therapy. We believe Neogene’s approach should result in a more efficacious product that can address a larger number of patients
- The company has not yet announced its target indications within the solid tumour field
- Complex manufacturing
- Complex early stage technology
- Highly competitive field
Key risks are Syncona team view